InterShunt Enrolls First Patient in New Heart Failure Study | Newswise

InterShunt Technologies, Inc., a medical device company focused on developing minimally invasive treatments for heart failure, has officially kicked off its latest clinical study, the EASE HF2 Early Feasibility Study, which is evaluating a device designed to reduce heart failure symptoms and improve quality of life.

Read More